We determined Cabergoline (ρ=−0.2918, q=0.0425), a dopamine receptor agonist (ADRA2C, DRD3, HTR1B, HTR2C, DRD1, ADRA2A, HTR2B, DRD5, DRD2, HTR1A, HTR2A, ADRA2B, DRD4, HTR1D, ADRA1A), among the negatively correlated drugs with sPC3 AD signature, and Fluphenazine (ρ=0.3632, q=0.0053), an antipsychotic, with positive correlation with the AD group, to be FDA approved and be able to cross the BBB (Figure 6B) (39,40). This evidence concerns the gene HTR2A and Alzheimer disease.